Skip to main content

Expanded Access Program of Palopegteriparatide in Patients With Hypoparathyroidism

Approved for marketing · NCT05654701

Conditions: Hypoparathyroidism

At a glance

Research payments reported, 2025
$528,918
U.S. investigators named
51
Sites paid
52

About the trial

Sponsor
Ascendis Pharma Bone Diseases A/S
Tested
Palopegteriparatide (TransCon PTH) (drug)
Results posted
Not yet

To provide palopegteriparatide (TransCon PTH), an investigational parathyroid hormone (PTH) replacement therapy in an expanded access setting for adult patients with hypoparathyroidism who have previously received PTH-treatment, who meet the eligibility criteria for this protocol as described below and have a clear unmet medical need that cannot be adequately treated by a commercial product or a clinical trial.

From ClinicalTrials.gov, last updated 2025-06-27. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Ascendis Pharma Endocrinology Inc reported $528,918 in research payments for this study in 2025 (1,015 payments).

Products named: Yorvipath

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

  • UCSF Langley Porter Psychiatric Hospital and Clinics, CA $65,009
  • Medical Center of the Rockies $48,320
  • Regents of the University of Colorado $27,066
  • Sutter Medical Center, Sacramento, CA $26,436
  • Lisa G Abbott, MD A Professional Corporation $24,651
  • The University of Chicago International House $23,150
  • Providence Medical Foundation $22,967
  • Thomas Jefferson University $20,092
  • Arthritis Northwest PLLC $19,162
  • The Ohio State University $18,003
  • Nyc Research, Inc. $16,582
  • University of Kentucky Research Foundation $15,691
  • Pejman Cohan, MD Inc. $14,643
  • University of Kansas Medical Center Research Institute, Inc. $13,248
  • Ohsu Hospital and Clinics, OR $12,348
  • Rutgers, the State University of New Jersey $12,062
  • The Feinstein Institutes for Medical Research $10,664
  • Healthy Mindset Intl $9,563
  • St. Lukes Hospital of Kansas City $9,337
  • St Elizabeth Edgewood, KY $8,974
  • Eric S. Langer, D.o. $8,337
  • Biopharma Informatic $8,006
  • Swedish Issaquah, WA $7,068
  • Oklahoma Heart Research and Education Foundation $6,652
  • Hoag Memorial Hospital Presbyterian $6,562
  • University of Pittsburgh Physicians $6,524
  • Board of Regents of University of Wisconsin System $6,323
  • Virginia Beach Premier Medical $6,173
  • Heritage Medical Associates, PC $5,405
  • The Trustees of Columbia University in The City of New York $4,958
  • Tucson Endocrine Associates, PLLC $4,587
  • Tampa Bay Diabetes Thyroid and Endocrinology Center $4,381
  • Physicians East, PA $4,380
  • Bryan Physician Network $3,799
  • West Virginia University $2,834
  • The University of Texas Health Science Center at Houston $2,499
  • Texas Diabetes & Endocrinology $2,492
  • Diabetes and Endocrinology Consultants of PA, LLC $2,422
  • Georgia Mountain Endocrinology, Corp $2,147
  • Ann Arbor Endocrinology and Diabetes Associates $2,006
  • Endocrinology Associates PA $1,896
  • Vivian O. Rodriguez, M.d.p.a. $1,790
  • Endocrine Associates of Long Island, PC $1,700
  • Veritas Research Group LLC $1,644
  • Hopehealth, Inc $1,633
  • Ohio State University State Health System, OH $1,499
  • Mohan Wellness Institute $1,283
  • Richard S. Cherlin $738
  • West Jefferson Medical Center, LA $726
  • Jeffrey Freeman $406
  • Univ. of Vermont - Fletcher Allen Health Care, VT $60
  • Laurel Endocrine Thyroid Specialist Inc $20

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.